Blocking LAG‑3 and PD‑1 to boost the immune response against glioblastoma
Targeting Lag-3 and PD -1 in Myeloid Cells of GBM
This work tests whether blocking two immune 'brakes' called LAG‑3 and PD‑1 can help the immune system fight glioblastoma in adults.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11309579 on NIH RePORTER |
What this research studies
If you join work like this, researchers aim to combine drugs that block LAG‑3 and PD‑1 to try to lift immune suppression inside glioblastoma tumors. They will study tumor and blood samples to see how myeloid cells and T cells change after dual blockade. The team builds on early clinical results that showed some patients had tumor responses and longer survival when both checkpoints were blocked. Lab studies and patient samples will be used together to understand why the treatment helps some people and not others.
Who could benefit from this research
Good fit: Adults (21+) with glioblastoma, especially those eligible for immune checkpoint therapy or clinical trials at the treating center, would be the most likely candidates.
Not a fit: People with medical conditions that prevent use of immune checkpoint inhibitors or whose tumors lack the immune features targeted by this approach may not benefit.
Why it matters
Potential benefit: If successful, this approach could strengthen anti‑tumor immunity and potentially improve outcomes for people with glioblastoma.
How similar studies have performed: Early clinical and preclinical work, including a Phase I trial, has shown promising responses in some GBM patients but the approach remains experimental and not yet widely proven.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Lim, Michael — Stanford University
- Study coordinator: Lim, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.